blue cross blue shield fep glp 1 coverage of Massachusetts will stop covering popular GLP-1 weight-loss drugs like Ozempic and Wegovy starting January 1, 2026. The decision comes as the costs for these medications have Tier exceptions no longer allowed

Teer says, As a not-for-profit health system, our passion for people extends beyond the walls of our care sites and into the diverse communities we serve

If food sounds completely unappealing, that must mean the medication is really working

Tier 4: Medical Intervention (When Indicated) Clinical obesity, type 2 diabetes, or other metabolic conditions requiring pharmaceutical management represent appropriate medical intervention contexts

Read More The FDAs removal of boxed warnings on certain hormone therapies marks a major shift in menopause care

There is ample evidence demonstrating the efficacy and safety of compounded GLP-1 treatments